UnknownPhase 2

Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia

Bolivia

Plain-language summary

The combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and antimony is chosen because these are now the two standard agents in Bolivia, and in vitro the combination was additive to mildly synergistic against a standard leishmania strain.

Who can participate

Age range18 Years – 65 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Gender: Male Age: Adults Presentation: At least 1 lesion must be ulcerative. Parasitology: Parasitological confirmation of 1 lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion. Exclusion Criteria: * Previous treatment for leishmaniasis, specific or putatively specific therapy (Sb, pentamidine, amphotericin B, imidazoles, allopurinol) * Other concomitant diseases by history and by approximately normal complete blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases (SGOT), values of pancreatic function (lipase), kidney function tests (creatinine), and EKG.

Trial details

NCT IDNCT00537953

SponsorCentro de Investigaciones Bioclínicas de la Fundación Fader

Sponsor typeOTHER

Study typeINTERVENTIONAL

Contact for this trial

Jaime Soto, MD

571 348 2171 j.soto@medplus.org.co

View on ClinicalTrials.gov More Cutaneous Leihmaniasis trials